NCT01860092终止不适用
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
Second Sight Medical Products17 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2014年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 53
- 试验地点
- 17
- 主要终点
- Safety subjects have reached 2 years post-implant.
研究概览
简要总结
This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.
详细描述
Safety data will be monitored to ensure continued acceptability of risks to study subjects. The utility (i.e. visual function and functional vision) and reliability of Argus II System will also be evaluated.
There is no study hypothesis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are adults, age 25 year or older;
- •Have severe to profound retinitis pigmentosa;
- •Bare light or no light perception in both eyes; if the patient has no residual light perception, then evidence of intact inner layer retina function must be confirmed;
- •Have previous history of useful form vision.
- •Aphakic or pseudophakic. (If the patient is phakic prior to implant, the natural lens will be removed during the implant procedure.)
- •Patients who are willing and able to receive the recommended post-implant clinical follow-up, device fitting, and visual rehabilitation;
- •Have consented to the implantation of an Argus II Retinal Prosthesis and subsequently consent to participate in this study;
- •At the time of the Baseline Visit, do not suffer from non-ophthalmic serious adverse events (e.g. myocardial infarction, etc.) and
排除标准
- •Ocular diseases or conditions that could prevent Argus II System from working (e.g. optic nerve disease, central retinal artery or vein occlusion, history of retinal detachment, trauma, severe strabismus);
- •Ocular structures or conditions that could prevent the successful implantation of the Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva, axial length <20.5 mm or >26 mm, corneal ulcers, etc.);
- •Ocular diseases or conditions (other than cataracts) that prevent adequate visualization of the inner structures of the eye (e.g. corneal opacity, etc.);
- •Inability to tolerate general anesthesia or the recommended antibiotic and steroid regimen associated with the implantation surgery;
- •Metallic or active implantable device(s) (e.g. cochlear implant) in the head;
- •Pre-disposition to eye rubbing;
- •Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
- •cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease,
- •psychiatric disease including diagnosed forms of depression;
- •does not speak a principal language associated with the region, and
- •deafness;
- •Pregnant or wish to become pregnant during the course of the study;
- •Participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study;
- •Conditions likely to limit life to less than 1 year from the time of inclusion.
结局指标
主要结局
Safety subjects have reached 2 years post-implant.
时间窗: 5 Years
Adverse event rates with the main safety analysis performed when all visits completed
次要结局
- Visual function(5 Years)
- Functional Vision(5 Years)
- Device Reliability(5 Years)
研究者
研究点 (17)
Loading locations...
相似试验
终止
不适用
Argus® II Retinal Prosthesis System Post-Market Surveillance StudyOuter Retinal DegenerationRetinitis PigmentosaNCT01490827Second Sight Medical Products52
已完成
不适用
Post-Market Study of the Argus® II Retinal Prosthesis System - FranceRetinitis PigmentosaNCT02303288Second Sight Medical Products18
已完成
不适用
Disrupt CAD III Post-Approval Study (PAS)Myocardial InfarctionCoronary Artery DiseaseNCT05021757Shockwave Medical, Inc.1,212
已完成
2 期
Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) ExtractAllergic RhinoconjunctivitisNCT01564017Roxall Medicina España S.A150
已完成
不适用
CentriMag RVAS U.S. Post-approval Study ProtocolRight Ventricular FailureNCT01568424Abbott Medical Devices25